Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2079996 | 0.83 | HRH4 (0.33) | HRH4PKMHRH3 | |
| SCHEMBL2951780 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL22495565 | 0.81 | CPB2 (0.32) | HRH4HRH3KDM4EKMT2A | |
| Trifluoroacetic Acid SCHEMBL321952 | 0.81 | NOS1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL16637695 | 0.80 | TSHR (0.31) | OPRM1KDM4EKMT2A | |
| Trifluoroacetic Acid SCHEMBL34474863 | 0.79 | — | — | |
| Trifluoroacetic Acid SCHEMBL21840084 | 0.79 | KDM4E (0.34) | HRH4PKMHRH3KDM4EKMT2A | |
| Trifluoroacetic Acid SCHEMBL23119996 | 0.77 | PIM1 (0.30) | — | |
| Trifluoroacetic Acid SCHEMBL3333797 | 0.76 | CYP2D6 (0.34) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL5035153 | 0.76 | CYP1A2 (0.42) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2142537-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008115973-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | OPRM1 4881/4885HRH4 2792/4885PKM 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.